Selecting Patients for Treatment with CO-1686
Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.
Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.
Clinical Pearls:
- The vast majority of patients with newly diagnosed lung cancer have an analysis of their EGFR genes looking for the activating mutations.
- This is done on tissue using PCR testing.
- Clovis Oncology uses a tissue-based T790M detection test for the identification of appropriate patients in clinical trials involving CO-1686.
- While there is a lot of interest in plasma as a way of detecting mutations in patients, it is not yet replacing tissue-based testing.​
Related Videos
Related Content
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024Article
At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
